Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts 'Upbeat'
In a market note, Mizuho raised its price target for Enliven Therapeutics Inc. (NASDAQ:ELVN) to $45 from $41 previously, while maintaining an “outperform” rating.
Enliven Therapeutics Inc. (ELVN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 7,959,538 | $122,576,885 | 2.5% | |
| 2. | Commodore Capital Egen Atkinson And Michael Kramarz | 4,692,809 | $72,269,259 | 4.81% | |
| 3. | Vestal Point Capital Ryan Wilder | 3,830,000 | $58,982,000 | +231% | 2.01% |
| 4. | Polar Capital Brian Ashford-Russell And Tim Woolley | 3,513,680 | $54,110,672 | +14% | 0.21% |
| 5. | Point72 Asset Management Steve Cohen | 1,504,601 | $23,170,855 | +45% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.07 | 622 | $13,723.27 | 718,749 | 2023-02-23 | Filing | |
| $5.11 | 23,565 | $120,487.85 | 2,872,513 | 2023-02-22 | Filing | |
| $5.25 | 8,194 | $43,010.31 | 2,848,948 | 2023-02-21 | Filing | |
| $4.00 | 629,297 | $2,516,055.27 | 3,880,021 | 2023-01-03 | Filing | |
| $3.93 | 19,299 | $75,845.07 | 3,250,724 | 2022-12-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.76 | 5,000 | $138,800.00 | 25,000 | 2026-03-17 | Filing | |
| $30.19 | 10,129 | $305,826.92 | 25,000 | 2026-03-10 | Filing | |
| $30.02 | 29,871 | $896,811.06 | 25,000 | 2026-03-09 | Filing | |
| $29.58 | 10,000 | $295,839.00 | 51,000 | 2026-03-06 | Filing | |
| $26.18 | 1,230 | $32,196.36 | 22,647 | 2026-02-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,107,635 | $109,457,572 | 0.01% | |
| 2. | 3,711,444 | $57,156,238 | 4.35% | |
| 3. | 3,613,326 | $55,645,219 | 0% | |
| 4. | 3,226,331 | $49,685,497 | 2.45% | |
| 5. | 2,801,665 | $43,145,640 | 0% |
News See All
10 Stocks Investors Are Buying Now: Chewy, Braze, Sarepta, and More
The company said that it has begun recruiting highly-skilled German talent to operationalize its upcoming satellite manufacturing facility in Berlin, as part of its plan to double the production capacity...
Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at Goldman Sachs started coverage on Enliven Therapeutics, Inc.
10 Best NASDAQ Stocks Under $50 to Buy
In this era where everyone is striving for the best, whether it be something in daily life or technology, the stock market is no exception.
Hedge Fund Resource Center